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The combination of dynamic 13C MRS data under infusion of 13C-labelled substrates and compartmental
models of cerebral metabolism enabled in vivo measurement of metabolic ﬂuxes with a quantitative and
distinct determination of cellular-speciﬁc activities. The non-invasive nature and the chemical speciﬁcity
of the 13C dynamic data obtained in those tracer experiments makes it an attractive approach offering
unique insights into cerebral metabolism. Genetically engineered mice present a wealth of disease
models particularly interesting for the neuroscience community. Nevertheless, in vivo 13C NMR studies of
the mouse brain are only recently appearing in the ﬁeld due to the numerous challenges linked to the
small mouse brain volume and the difﬁculty to follow the mouse physiological parameters within the
NMR system during the infusion experiment. This review will present the progresses in the quest for a
higher in vivo 13C signal-to-noise ratio up to the present state of the art techniques, which made it
feasible to assess glucose metabolism in different regions of the mouse brain. We describe how exper-
imental results were integrated into suitable compartmental models and how a deep understanding of
cerebral metabolism depends on the reliable detection of 13C in the different molecules and carbon
positions.
© 2017 Elsevier Inc. All rights reserved.1. Introduction
Since its ﬁrst appearance in the ﬁeld of brain biomedical im-
aging in the early ‘90s [1e6], 13C MRS has been facing arduous
challenges in enhancing in vivo sensitivity and spatial resolution in
small localized volumes. All these efforts were motivated by the
unique potential and promise of the 13C isotope in exploring
metabolism, enabling the measurement of metabolic rates in intact
organs in vivo. Different approaches in NMR signal measurement
have been developed to overcome limitations induced by the
inherent low sensitivity of 13C detection, associated with its low
natural abundance (1.1%) and gyromagnetic ratio. To meet the need
for signal localization in brain MRS, which is essential in order to
remove lipid contamination from the scalp and access regional
metabolic rates, NMR sequences had to be adapted.F1 622 (Ba^timent CH), StationAfter pioneering in vivo 13C MRS detection of brain metabolites
in the rabbit under infusion of [1e13C]Glc [7], 13C MRS showed
successful results on the human brain. Although most of the early
13C MRS human studies were based on detection of natural abun-
dance signals [1,2,5,6,8], the technique met its wider success with
the combined injection of 13C-enriched substrates like glucose and
acetate, as single or multiple substrate intravenous administration.
These substrates in their different isotopically labelled forms
enabled speciﬁc insights on compartmentalized cerebral meta-
bolism in the healthy brain and in various brain diseases in human
and animal models when combined with 13C metabolic ﬂux anal-
ysis (MFA). In 13C-labelling experiments, the fate of the adminis-
tered substrate into different metabolic pathways can be analysed
by taking advantage of a key asset of 13C MRS, namely the distinct
chemical shift of the 13C isotope in different molecules and in
different carbon positions in the same molecule. Moreover, in
highly resolved 13C spectra, the appearance of 13C-13C J-coupling
allows additional isotopomer analysis, reaching a new frontier in
brain 13C MFA. 13C isotopomer analysis was ﬁrst pioneered in the
’80s in studies of perfused heart [9e12] based on single time point
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whole time course of 13C isotopomers appeared only recently in
brain metabolic studies, due to the inherently low sensitivity of 13C
detection and limited spectral resolution to observe homonuclear
coupling. The advent of ultrahigh ﬁeld systems and improved
detection methods enabled this reﬁned analysis [13e16].
The use of animal models combined with brain 13C MRS opens
the perspective of a deeper understanding of neurometabolic as-
pects in a wide range of brain disorders [17]. Within all animal
models, mice and rats play a central role in biomedical research.
Although in vivo 13C MRS is not yet routinely applied in rodents,
several studies already demonstrated its feasibility in the rat brain
with its associated MFA [18e26] while analogous mouse brain 13C
MRS experiments are only recently appearing [27e31], reaching a
new standard of sensitivity in 13C detection. This delay is mainly
explained by the reduced size of the mouse brain, which affects
SNR noticeably and by the small blood volume in the mouse body,
which complicates the measurement of the plasma input function
by serial blood sampling, a key element of MFA.
This reviewwill examine howmajor developments in in vivo 13C
MRS in human and rat brain have been translated to mice at ul-
trahigh ﬁelds. Technical aspects and methodology of a typical
in vivo experiment will be at ﬁrst presented, followed by consid-
erations on the impact of magnet ﬁeld strength, NMR sequences
and RF coils on sensitivity. MFA for compartmental modelling will
be examined together with the essential ingredients for estimation
of metabolic ﬂuxes. Technical advances in spectral and spatial
resolution will be described from a historical perspective, starting
with the ﬁrst 13C labelling experiments to the present state-of-the-
art techniques in in vivo 13C MRS in rodents. At last, most recent
results in mice experiments will be presented together with their
impact on modelling strategies.2. In vivo 13C MRS in mice: overview of a general experiment
This review will focus on 13C-labelling experiments in rodents
with intravenous infusion of a labelled substrate. Mice experiments
are generally based on the same kind of setup as for rat experi-
ments, which appeared earlier in the ﬁeld for practical reasons,
both from the physiological and physical points of view. In a rat
experiment, animal preparation is already quite challenging,
including the arterial/venous cannulations, substrate infusion,
monitoring of anaesthesia and physiological parameters, artiﬁcial
ventilation and recurrent blood sampling during the whole dura-
tion of the experiment. Given the reduced anatomical size in mice,
surgical interventions are more critical, since blood vessels are
smaller and more fragile, which requires additional caution during
manipulations. In rats, surgical intervention includes typically avenous catheter for the injection of the labelled substrate and a
second one for arterial blood sampling (Fig. 1A). Blood samples are
usually employed to measure glycemia as well as other substrates
concentration and fractional enrichment (FE) with high resolution
NMR or gas chromatographyemass spectrometry: they are typi-
cally collected from a long catheter accessible from outside the
magnet bore during the 13C-labelling experiment, implying the
withdrawal of a relatively large volume of blood before sampling,
due to the related dead volume. The blood withdrawn is usually
reinjected through the same line at the end of each sampling
procedure to minimize losses. Blood volume in mammals is esti-
mated around 6e7% of total body weight [32e34] resulting in less
than 2 mL in a mouse of 30 g compared to around 18 mL in a rat of
270 g [35,36]. This allows repetitive blood sampling in rats over a
short duration (several hours) as each sample represents about 1%
of the total blood volume (typically ~250 mL), as recommended by
ethical guidelines [35e37]. Similar constraints applied to mice
result in around 10 mL of volume for repeated sampling which is not
compatible with experimental needs. Even if the sample would be
limited to a signiﬁcantly small amount sufﬁcient for glycemia
measurements, it would even so cause a signiﬁcant physiological
stress due to the rapid decrease in total blood volume during the
sampling procedure. Several symptoms would appear among
which, a sudden decrease in body temperature and arterial pres-
sure that will ultimately inﬂuence cardiac output [38]. If the blood
loss reaches 15e20% of the blood volume, compensatory effects
would impact the whole body metabolism, including switching to
anaerobic glycolysis and acidosis [38], peak rise of blood sugars and
fatty acids [39] due to a general hypercatabolism [40]. For these
reasons, blood measurements were usually only performed at the
end of the experiment for mice in in vivo 13C MRS studies [27,28].
Bench experiments performed on a subgroup of similar mice can
help to characterize the effect and variability of the infusion pro-
tocol and anaesthetics on the blood parameters. Infusion protocols
are typically adapted to the speciﬁc mouse strain, as well as to the
age and sex. In fact each phenotype shows distinct responses to the
same protocol caused by speciﬁcities in their endocrine systems
among others.
For brain 13C-labelling experiments in horizontal MRI magnets,
rodents usually lye prone in the magnet bore with an adapted RF
coil on the top of their head (Fig. 1A). Anaesthesia can be admin-
istered intravenously as frequently done in rats [22,25] but mice
protocols more commonly make use of air mixture of volatile an-
aesthetics, such as isoﬂurane [27e29,41] with freely breathing
animals. Substrates are typically administered through the venous
circulation with a catheter placed in a tail or femoral vein. In our
group, tail vein lines are connected to a 25G (0.5 mm outer diam-
eter) needle for the injection while a smaller catheter of 26G
(0.46 mm outer diameter) is used for femoral vein cannulation The
labelled substrate is carried to the brain by the blood circulation,
before being taken up through the blood-brain barrier (BBB).
Therefore, a precise determination of temporal variation of sub-
strate labelling in plasma, i.e. the arterial input function, is crucial
for MFA [42,43]. For this reason, intraperitoneal injections are
avoided as they give rise to inconsistent release of the injected
substance in plasma. Central to many 13C MRS labelling experi-
ments in the brain is the measurement of mitochondrial oxidative
metabolism in the tricarboxylic acid (TCA) cycle as well as further
13C transfer to amino acids, and neurotransmitter cycling. Those
biochemical processes are downstream to glucose uptake and
metabolism. To achieve optimal characterization of these reactions,
an infusion protocol for the entire duration of the experiment is
typically designed aiming at reaching a high FE in the blood (on the
order of 50e90%) and saturation in the transport through the BBB
for the labelled substrate. Transport towards the brain is in fact a
Fig. 1. General setup of a representative in vivo 13C MRS experiment in the rat brain (A): the animal is anesthetized with volatile anaesthetics and it lies prone in the magnet with a
surface coil on the top of its head. Arterial and venous femoral catheters are put in place in order to access serial blood sampling and allow substrate injection, respectively. The
infusion protocol aims to build a step function as plasma input function, by reaching a relatively high level of fractional enrichment for the substrate of choice in the plasma in a
short time (<5 min) and maintaining it stable for all the duration of the experiment (B). 13C dynamic spectra show progressively rising peaks of the metabolites carbon positions of
glutamate and glutamine and other by-products with sufﬁciently large pool size (C). Displayed spectra are derived from in vivo 13C direct detection in the mouse brain within the
ﬁrst 50 min of infusion of [1,6e13C]glucose at 70% FE. Quantiﬁed concentrations of each carbon position from the spectra will constitute the dynamic data set (D) further analysed
with MFA to get quantitative information on the metabolic ﬂuxes characterizing the biochemical system under study, typically TCA activity and glutamate/glutamine cycling.
Abbreviations: glucose (Glc), glutamate (Glu), glutamine (Gln), lactate (Lac).
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tions as shown for glucose [44], lactate [45] and acetate [46]: this
results in a nearly constant extraction rate of the tracer from the
blood to the brain compartment, an essential condition to work
under metabolic steady state. The 13C-glucose infusion protocol
typically consists in a rapid exponentially decaying bolus of 99%
enriched glucose, followed by an adjustable continuous infusion of
a lower enrichment glucose (typically 60e70%), designed to result
in a plasma step function for the labelled precursor fractional
enrichment (Fig. 1B). For glucose, an ideal exponential bolus lastsFig. 2. (A) Representative scheme of a compartment, modelled as an ensemble of single m
connection with the external environment. (B) A single metabolic pool scheme with n inﬂux
…, Pm) are generated from the considered metabolic pool through corresponding chemical re
with a fractional enrichment S
*ðtÞ
½S ) and efﬂux, with the addition of a dilution ﬂux Vdil that br
state

P*
½P

.about 5 min where the decaying constant is determined in order to
administer almost half of the glucose solution in the ﬁrst minute.
The total bolus volume is calculated based on the animal body
weight and the basal glycaemia prior to injection, in order that at
the end of the bolus, blood glucose FE reaches the value of the
second solution used for the continuous infusion. In this process,
the glycemia rises from its basal value (90e110 mg/dL after fasting)
to a high value of about 250e300 mg/dL, which also ensures
saturation of the transport across the BBB. Such a step input func-
tion is of advantage due to its simplicity when aiming at MFA of theetabolic pools connected by metabolic ﬂuxes. One or several pools can be in direct
es (V1in,…, Vnin) coming from n corresponding substrates (S1,…, Sn). The products (P1,
actions (V1in,…, Vmin). (C) Example of a metabolic pool with a single inﬂux (substrate S
ings unlabelled isotopes to the product P, reducing the fractional enrichment at steady
Fig. 3. (A) Three-compartment model of glucose metabolism accounting for trafﬁcking between glial cells, GABAergic and glutamatergic neurons. The ﬂuxes related to the
GABAergic compartment (shown in grey) can be excluded from the modelling strategy leaving a two-compartment model for neurons and glial cells. (B) Labelling scheme deriving
from the infusion of [1e13C]glucose and [1,6e13C]glucose with particular attention to labelling of glutamate (Glu), glutamine (Gln), GABA and aspartate (Asp) in the carbon positions
usually reported in in vivo 13C experiments with direct and indirect detection. Oxaloacetate (OAA), 2-oxoglutarate (OG) and other TCA cycle intermediates are usually in low
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M. Lai et al. / Analytical Biochemistry 529 (2017) 229e244 233data, usually reaching high values of FE to increase 13C concentra-
tion in the by-products of the metabolism under study and reach
sufﬁcient SNR for an accurate 13C spectral quantiﬁcation. For 13C-
glucose experiments, the desired plasma FE generally lies between
50 and 70% as a compromise between the need for higher 13C
concentration to improve sensitivity and the necessity to maintain
the plasma levels of nutrients near physiological conditions. Typical
infusion rates for euglycemic clamps are 9.96 mL/kg/h with a 20%
mass/volume solution of glucose [47], which stabilises the plasma
glucose level over time. A stable enrichment of the precursor in the
plasma will lead to a progressive labelling of the downstream
metabolites: the duration of the experiment is typically long
enough to sufﬁciently characterize the labelling curve for each
carbon position that is included in the model (Fig. 1C). Therefore,
the required infusion time directly depends on the metabolism
under investigation, on the desired level of details in the metabolic
modelling of the data and on the cost of the substrate: as an
example, when studying glutamate and glutamine turnover in the
brain in order to characterize TCA activity in the separate neuronal
and glial compartments under glucose infusion, 4e5 h of labelled
glucose infusionwould be desirable to reach a labelling steady state
in C4, and high FE in C3 and C2 positions of glutamate and gluta-
mine [19,22,23,29]. A longer time is needed for C2 and C3, since
multiple cycling of the TCA cycle and the slower pyruvate carbox-
ylase reaction characterize their build-up (Fig. 3B). However, such a
long infusion experiment is not always compatible with the
maintenance of a proper physiology under euglycemia or hyper-
glycemia, or with the tolerance of the subject, in particular for
human studies. A good compromise has to be found for the
experimental time, since an accurate measurement of the metab-
olites 13C enrichment over a duration compatible with glutamate/
glutamine turnover rates is essential to ensure accuracy and
robustness in neuro-glial modelling, as distinct detection of C3 and
C2 turnover curves is critical in distinguishing the glial compart-
ment metabolism [43,48]. Dynamic experimental data of the
temporal evolution of the 13C-enriched metabolites (Fig. 1D) are
integrated in a suitable metabolic model to estimate the ﬂuxes of
the metabolism under investigation by non-linear regression pro-
cesses. The pool sizes of the metabolic model are determined from
the total concentration of the metabolites quantiﬁed with 1H MRS
prior to the substrate infusion [29] or alternatively from analysis of
brain extracts ex vivo [19,23,25].
Challenges particular to mice experiments mostly concern the
inaccessibility to the arterial input function due to the limited blood
volume as discussed above (1.5e2 ml). A standardized infusion
protocol, designed on the base of bench experiments is an alter-
native to a direct measurement of the arterial input function that
can be applied for metabolic modelling. Alternatively, speciﬁc 13C
detecting techniques such as 1H-[13C] MRS indirect detection
[28,30,31], enable real-time measurement of the fractional
enrichment of certain intermediates of brain glucose metabolism
during the experiment. An example is the use of the measured FE of
lactate in the 1H-[13C] MRS tissue voxel which can be used as an
input function for the TCA cycle, representing the temporal evo-
lution of pyruvate FE. This approach takes advantage of the fast
exchange between pyruvate and lactate through lactate dehydro-
genase (LDH) as compared with the TCA cycle rates [28]. In addi-
tion, it gives an input function which is closer to the processes ofcentration (below 1 mM) and therefore invisible in in vivo applications in the brain. Oth
colytic ﬂux (Vgly), lactate dehydrogenase (LDH), pyruvate dehydrogenase ﬂux (PDH), speciﬁc
uvate carboxylase ﬂux (VPC), total glial TCA cycle (VTCAg ¼ Vg þ VPC), neuronal TCA cycle (VTCAn
x (VGS), glutamine efﬂux rate (Vefﬂux), GABAergic TCA cycle (VTCAGABA), glutamate decarboxylase
e subscripts 1,2,3,… indicate which position in the carbon chain is labelled for a given metainterest in terms of biochemical reactions network, the TCA cycle
and neurotransmitter exchanges, accounting therefore directly for
possible upstream dilutions in glucose uptake and glycolysis
process.
2.1. Sensitivity and dependence upon B0
Due to physical properties of the carbon nucleus, 13C MRS is a
relatively insensitive technique compared to 1H and 31P MRS. At
thermal equilibrium, the NMR signal intensity depends on the total
magnetization, which linearly depends on the applied polarization
ﬁeld B0, according to the following relationship [49]:
M0 ¼

gh
2p
2nB0
4kT

(1)
where g is the gyromagnetic ratio, h the Planck constant, n the
number of spins in the sample contributing to the magnetization
build-up, B0 the static magnetic ﬁeld, k the Boltzmann constant, T
the temperature of the sample and M0 the macroscopic nuclear
magnetization upon which the MRS signal depends. Sensitivity
differences linked to the nucleus of choice are dependent on
respective gyromagnetic ratios, yet an increase in the static mag-
netic ﬁeld will be beneﬁcial for all MRS techniques regardless of the
detected nucleus. This linear dependency encouraged a steady in-
crease in magnetic ﬁeld strength in the last decades, especially for
animal studies. An increase in B0 also increases the difference in
resonance frequencies of nuclei in different chemical environment,
the chemical shift range [49], reducing peak overlap: this increased
separation is of importance when simultaneously detecting mole-
cules which have a similar carbon skeleton such as glutamate and
glutamine. At 9.4 Tesla and higher ﬁelds, the C4, C3 and C2 reso-
nances of glutamate and glutamine appear fully resolved when
using direct detection techniques in the rat brain in vivo [22,50]
while hydrogens linked to C3 and C2 of glutamate overlap with
those of glutamine when applying 1H-[13C] MRS indirect detection
[20,28]. However, recent acquisition of in vivo data at 9.4 and 14.1
Tesla with indirect detection approaches showed the possibility to
distinguish between C3 resonances of glutamate and glutamine in
the rat brain during the infusion of [U-13C]Glc, [1,6e13C]Glc at 14.1
Tesla and [2e13C]Ace at 9.4 Tesla [21,30,51].
The equilibrium magnetization M0 is generated by the spin
population with a proportion of spins aligned with the external
ﬁeld increasing linearly with B0. Due to Faraday's law of induction,
the amplitude of the signal induced in the RF coil by the precessing
magnetization depends on the Larmor precession frequency as
follows:
Sfu0Mxy with u0 ¼ gB0 (2)
where S is the NMR signal amplitude, Mxy the transverse compo-
nent of the macroscopic magnetization (initially proportional to
M0) and u0 the Larmor precession frequency. In other words, a
more intense electrical current is generated for higher Larmor
frequencies for a given nucleus. Based on this effect and on Eq. (1)
the signal S would theoretically be proportional to B02 [52e54]. For
in vivo applications, the sample reasonably constitutes the domi-
nant source of noise detected by the same principle of induction.er abbreviations: glucose (Glc), lactate (Lac), pyruvate (Pyr), acetyl-CoA (AcCoA),
glial dilution from glial-speciﬁc substrates (Vdilg ), dilution of the lactate pool (Vout),
), transmitochondrial ﬂux (Vx), neurotransmission ﬂux (VNT), glutamine synthetase
ﬂux (VGAD), ﬂux of GABA catabolism (Vshunt), GABAergic neurotransmission (VGABA).
bolite.
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on B0 linearly, resulting in a global linear dependence on B0 for the
SNR. Nevertheless, these considerations are not including all the
factors inﬂuencing SNR in a MRS experiments: the entire experi-
mental setup will inﬂuence the noise level, among which the noise
generated by the RF coil and its efﬁciency in detection and trans-
mission, the efﬁciency in the shimming techniques and hardware
noise injection in the signal ampliﬁcation processes, in addition to
relaxation mechanisms and their dependency upon B0. The de-
pendency of the MRS signal on the natural abundance level of the
13C isotope will not be discussed further, since this review focuses
on experiments performed under infusion of 13C-enriched sub-
strates that are meant to increase the FE for the metabolites of
interest well above natural abundance.
Considering the size of the brain of rodents and in particular,
comparing rat brain with mouse brain, there is an obvious draw-
back on the sample size that will result in reduced signals in mice
experiments. MRI morphometric measurements on rats above
200 g body weight estimate their total brain volume to around
1.7 cm3 [55] while 8 weeks old mice brain imaged ex vivo resulted
in an average of 0.4 cm3 [56]. Furthermore, the mouse brain con-
tains very similar complex cerebral structures in a smaller volume:
this results in a higher density of interfaces between tissues and air-
tissue with different magnetic properties, negatively affecting the
B0 ﬁeld homogeneity. The higher tissue heterogeneity at equal
volume is further ampliﬁed at higher ﬁeld strengths, since differ-
ences in susceptibility between different adjacent tissues are pro-
portional to B0, resulting in a broadening of the linewidth. State of
the art shimming techniques for rectiﬁcation of ﬁeld in-
homogeneity become therefore critical for small volumes and/or
strong B0 and require at least 1st and 2nd order shimming that are
commonly based on automated ﬁeld mapping [57,58]. Rat experi-
ments in which those techniques are implemented reported line-
widths of 10e13 Hz for the water peak in a localized volume of
100 mL at 7 Tesla [20] while other authors measured 14e16 Hz in
180 mL at 9.4 Tesla [21] and 20e22 Hz in 144 mL at 14.1 Tesla [51].
Similar experiments performed inmice reportedwater linewidth of
24e28 Hz in 60 mL at 14.1 Tesla [28] whereas 27e30 Hz were ob-
tained in 175 mL at 7 Tesla with manual localized shimming [27].
2.2. Direct and indirect 13C detection
The molecules of biochemical interest detected in brain 13C MRS
are typically characterized by carbon nuclei linked to 1H (NA
>99.9%), 16O (NA 99.8%) and 14N (NA 99.6%) nuclei. 16O has a
magnetically inactive nucleus and does not interact with the 13C
nuclear spin. By contrast, heteronuclear scalar coupling between 1H
and 13C generates peak satellites symmetrically placed around the
13C main resonances, appearing as doublet/triplet patterns or
combinations of them, due to the coherent nature of the spin-spin
coupling effect [59]. Spectral splitting due to 1H-13C coupling
noticeably lowers the SNR by complicating the spectral resonance
pattern and lowering the individual peaks amplitudes (in addition
to homonuclear 13C-13C splitting), making broadband 1H decou-
pling particularly beneﬁcial. Since the ﬁrst 13C MRS applications in
cells and microorganisms [60e63] and rats [64,65], it appeared
obvious that indirect detection of the 13C nuclei through their
neighbour 1H nuclei would improve experimental sensitivity
dramatically by making full use of the higher proton gyromagnetic
ratio. As pointed out in the previous paragraph, the NMR signal
depends on M0 and u0, thus the gain in signal intensity for indirect
detection depends on g3 [66]. The increase of noise induction upon
the Larmor frequency will reduce the global gain in SNR to g2. The
improvement would theoretically reach a 16-fold factor but these
observations neglect the effects linked to 1H-1H coupling andmultiplicity in the CH groups, as discussed elsewhere [42,66]. The
overall spectral resolution is moreover inﬂuenced by the different
linewidth obtained via direct 13C detection compared with 1H
detection, due to the slower T2 relaxation [67]. Moreover, opting for
indirect detection techniques is made at the expenses of a narrow
chemical shift range of the resonances of interest, resulting in
strong signal overlap (that will preclude detection of metabolites of
low concentration and 13C isotopomer analysis), the need for water
signal suppression methods and broadband 13C decoupling. Glob-
ally, the choice between direct or indirect detection represents a
trade-off between the amount of chemical information that will be
available for metabolic modelling and the sensitivity (i.e. spatial
and temporal resolution) needed in the experiment.
2.3. RF coil designs for in vivo 13C MRS in rodents
Initial in vivo 13C experiments in the late 80s and 90s made use
of 13C-1H transmitter-receiver RF surface coils consisting in two
concentric and co-planar loops [4,7,64,65,68e71], where the
smaller one is tuned at the lower frequency (13C) and the larger one
to 1H. Nowadays, 13C-1H surface coils are still largely preferred over
volume coils due to the higher sensitivity achievable in the 13C
signal detection over a spatially localized region, mainly due to a
better match between the coil sensitive volume and the sample size
(ﬁlling factor) as well as the higher B1 transmit ﬁeld, of great in-
terest for the large chemical shift range of 13C resonances. None-
theless, studies report 1H volume coils used for heteronuclear
decoupling in combination to 13C surface coils: this setup strongly
reduces inhomogeneities of the B1 ﬁeld at the 1H frequency
[27,72e74] and is especially suitable in human studies up to 3 Tesla,
to address the requirements in terms of power deposition during
decoupling.
Surface coils with co-planar concentric loops were proposed in
the late 80s [75e77] and had successful applications in vivo espe-
cially at low ﬁelds. Their relatively limited performance in terms of
SNR, due to interferences between the loops, became restrictive for
high ﬁeld applications. The same problems affected double-tuned
surface coils that became obsolete nowadays [78,79]. In addition,
the heteronuclear scalar coupling between 1H and 13C is relatively
large (1JCH ¼ 120e170 Hz) and the related decoupling power also
increases at higher ﬁeld due to an increased decoupling bandwidth
required for the same chemical shift range. Globally, the power
requirements for decoupling depend on the square of the RF fre-
quency (i.e. B02) for a given bandwidth (in Hz) and on B12 when
increasing the decoupling bandwidth [80], becoming restrictive at
high ﬁeld strengths, both from the safety point of view and the
available RF ampliﬁers [81].
Innovative RF coil designs were inspired by the need to meet
safety guidelines [82,83] for human experiments, but they also
inﬂuenced decades of applications in animal experiments. Single
13C loop associated with a double 1H-coil in quadrature conﬁgu-
ration became the most popular set-up as surface coil for direct
detection techniques [84]: the main advantage in humans consists
in the higher ﬁlling factor due to an adapted geometry between the
coil and the sample, when the voxel is located near to the surface of
the head, which is a condition easier to meet in mice [85]. More-
over, the geometrical decoupling between the 1H loops and the 13C
coil electrically isolates the two channels, resulting in optimal SNR
during 13C signal detection and avoids noise injections during 1H
decoupling. This is typically reinforced by adding bandpass ﬁlters
on the 1H and 13C channels. The RF transmit power is also halved
during 1H decoupling bymaking use of the coil quadrature. Indirect
detection can be achieved efﬁciently by using the same conﬁgu-
ration with inversion of the 1H and 13C channels. The use of adia-
batic pulses greatly increased the transmission efﬁciency of surface
M. Lai et al. / Analytical Biochemistry 529 (2017) 229e244 235coils over larger regions, overcoming the intrinsically high in-
homogeneity in the B1 ﬁeld strength of these coils. First efforts were
initially made in developing adiabatic full passage and half-passage
pulses [86] that however cannot perform plane rotations, i.e. ro-
tations are only effective for magnetizations that are collinear with
the longitudinal axis. For this purpose, plane rotations adiabatic
pulses were invented [87], which allow a constant rotation of any
desired ﬂip angle over a wide and symmetric bandwidth, despite
the RF inhomogeneity [88], an advantageous condition for 13C MRS
in vivo applications.
RF coils are frequently home-made and adapted to the anatomy
of the mice. 1H coil loops required for mice experiments have di-
ameters in the order of 12e15 mm [28e30], therefore covering the
entire mouse brain for 1H surface coils in quadrature conﬁguration.
The respective 13C loop has usually a smaller diameter (9e10 mm),
more comparable with the voxel size [28e30], which constitutes an
advantage in terms of sensitivity since the 13C loop is close to the
localized region under study while the larger 1H coil is commonly
designed to simultaneously work for decoupling, 1H localization,
shimming and imaging the entire brain. All brain regions are
virtually close to the coil when compared to a human surface coil,
although sensitivity varies substantially along the coil axis due to B1
inhomogeneity, which can nevertheless be mitigated with the use
of adiabatic pulses for excitation. However, it could be expected
that inhomogeneities in the B1 ﬁeld over the sample are reduced in
mice due to the relative size of the coil compared to the brain: the
Biot-Savart law dictates that the B1 ﬁeld on the loop axis has a
penetration depth of approximatively a coil radius, so that theo-
retically the sensitivity would scale as r1 when other sources of
loss are neglected [89]. Since the 13C loop diameter is usually
comparable with the brain diameter in mice, the B1 ﬁeld will
penetrate more than in the human brain where the size of the loop
(80e100 mm [90]) is much smaller than the diameter of the brain.
The size of RF coils compared to the animal or human head is of
great inﬂuence to the source of noise as well, even if the same
design is used. Sample losses are indeed dominant in RF coils for
human applications, where the localized signal usually comes from
a relatively small region while the coil is loaded by the whole head.
Conversely, all sources of losses are equally important while
detecting 13C signal in small rodents, where the total 13C signal is
reduced due to the smaller volumes but the sample losses are
reduced as well: hardware elements (coil, capacitors and trans-
mission line) and the sample equally contribute to the noise level
[85]. Cryogenic coils are commercially available and represent a
solution to lower the noise sources coming from the coil and pre-
ampliﬁer. Nevertheless, cryogenic coils are maintained under a
strong temperature gradient between the chilled circuitry and the
surface close to the sample, impeding a close proximity to the
mouse head that can be accomplished with room temperature coils
[41].
3. Metabolic ﬂux analysis
The strong asset of 13C MRS in studying brain metabolism
mostly resides in the possibility of quantifying metabolic ﬂuxes of a
range of biochemical reactions involved in the metabolism of the
injected labelled substrate. This is made possible by the high level
chemical speciﬁcity of 13C MRS, as compared to radionuclei-based
labelling studies. The chemical shift of 13C resonances not only
carries information on which molecule species is labelled, but also
at which position of the carbon molecule backbone. Distinguishing
between labelling levels in the precursors and different by-
products of given biochemical reaction chains enables insight into
brain energy metabolism and neurotransmitter cycling. This com-
plex set of information is measured dynamically over time andfurther analysed with a suitable mathematical model, summarizing
the key neurochemical reactions involved in the labelling of the
measured molecules. The free parameters of the model, typically a
set of metabolic ﬂuxes, are adjusted through a regression process in
order to get the labelling model functions that best describe the
in vivo measured kinetics, resulting in a set of characteristic ﬂux
values. This complex set of quantitative information onmetabolism
makes the whole effort against the poor 13C sensitivity issue
worthwhile. Another technique which greatly enhances 13C signal
in vivo is the employment of hyperpolarized substrates. However,
sophisticated MFA is trickier to apply in this context, since rather
than absolute 13C metabolite concentrations, signal ratios of
different 13C peaks are obtained, subject to polarization decay by
relaxation and RF excitation.
The most common modelling approach in 13C MRS is compart-
mental modelling where the organ, tissue or any biological unit
under study is depicted as an ensemble of distinct subunits where
the label enters and can move through a deﬁned metabolic
pathway [91,92]. Nowadays metabolic models for brain kinetics
frequently include two or three compartments accounting for cell-
speciﬁc metabolism: most of the models describe neuro-glial
interaction while fewer attempted to discern between GABAergic
and glutamatergic neurons [21,93,94], mostly ex vivo [95,96]. On
the other hand, spectra acquired with indirect detection techniques
are typically analysed with a one-compartment approach given the
frequent overlap between C3 and C2 positions of glutamate and
glutamine [28,30] and the induced limitations on biochemical
information.
In compartmental modelling, the biological system under study
is divided in a ﬁnite number of compartments and metabolic pools,
representing different molecules and carbon positions within these
molecules, connected by metabolic ﬂuxes (Fig. 2A) [43]. A
compartment is characterized by an ensemble of metabolic pools
which behaves homogeneously in a tracer study since it is governed
by a characteristic structure from the chemical point of view. A pool
is a portion of the compartment characterized by an homogeneous
kinetics (Fig. 2B), meaning that any product entering with an inﬂux
is instantaneously mixed and indistinguishable [97,98], or in other
words each molecule of a given pool has the same probability of
leaving it through an efﬂux. The metabolic ﬂuxes deﬁne the rele-
vant chemical reactions or set of chemical reactions as well as the
transport processes of the molecules across cellular and tissue
membranes, such as the transport of the substrate through the BBB
from plasma to the tissue compartment. An accessible compart-
ment is used for the introduction of the labelled substrate of choice
(i.e. plasma compartment) and its fractional enrichment over time
is known as input function. The system being isolated, it is subject
to several constraints dictated by mass-balance equations. Meta-
bolic steady state is usually assumed, which means that total con-
centrations of the metabolic pools as well as metabolic ﬂuxes are
constant throughout the infusion experiment. Studies tracking the
time evolution of the pool sizes, as possiblewith 1H-[13C]MRS, have
shown that the assumption of constant metabolic pool sizes is
admissible for studies with infusion of 13C-glucose [3,48], while it
might need reﬁnement for other substrates, such as for [2e13C]
acetate, where an increase in glutamate was measured [99].
The following paragraph will illustrate how differential equa-
tions can describe metabolite kinetics in a single-pool and more
complex models. The ﬁtting procedure and Monte Carlo simula-
tions to evaluate the precision of the parameters determinationwill
be brieﬂy presented.
3.1. Kinetics of a single pool
The labelling pool is the smallest unit of a compartmentalized
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ﬂux and an efﬂux will be considered with the analytical repre-
sentation of its labelling time course as an illustrating example. A
generalization to a generic number of labelling pools and ﬂuxes will
then be described.
In 13C labelling experiments, the total concentration of labelled
and unlabelled metabolite deﬁnes the pool size. Each metabolite is
the product (P) of one or multiple chemical reactions in the system.
The variation over time of the total product concentration corre-
sponds to the difference between the incoming ﬂux (Vin) and the
efﬂux (Vout), following the mass conservation principle [43,48]:
dPðtÞ
dt
¼ Vin  Vout (3)
The metabolic steady state assumption implies dPðtÞdt ¼ 0, hence:
Vin ¼ Vout (4)
Once the labelled substrate is administered through the plasma,
the concentration of labelled product (P*) will start increasing. The
ratio between the labelled form of the product and its pool size ½P is
deﬁned as the FE of the pool. The variation in the labelling con-
centration of the product of the product P is governed by the
labelling equation:
dP*ðtÞ
dt
¼ S
*ðtÞ
½S Vin 
P*ðtÞ
½P Vout (5)
where each ﬂux is multiplied by the time-dependent FE of the
metabolite in its compartment of origin. The function S
*ðtÞ
½S for the
substrate injected in the plasma (i.e. the input function of the
experiment) is frequently determined by serial blood sampling or
imposed by a priori knowledge, whereas the fractional enrichment
of the product P
*ðtÞ
½P is measured from the in vivo
13C MRS data. With
the metabolic steady state condition, the differential equation can
be solved and the solution adjusted to the measured enrichment
time course for the determination of Vin and Vout . In this case, the
situation reduces to the quantiﬁcation of a single parameter since
Vin ¼ Vout .
In a general scheme (Fig. 2B), the pool i of the biological system
under study will be characterized by n ﬂuxes that will generate an
inﬂux and m generating an efﬂux.
The labelling equation for a single pool is a ﬁrst order linear
differential equation that can be solved analytically in the general
form [43]:
P*ðtÞ ¼
Zt
0
Vin
S*ðtÞ
½S exp

Vout
½P

t
0  t

dt0 (6)
This equations can be further simpliﬁed by applying the con-
dition of metabolic steady state (i.e.Vin ¼ Vout), and employing the
easiest shape for the input function, namely a step function. In this
case, the FE of the substrate will be nearly zero at t ¼ 0 and it will
raise to a constant level S
*
½S at t >0. The analytical form of the
labelling curve in the product pool will simplify to:
P*ðtÞ
½P ¼
S*
½S

1 exp

 Vin½P t

(7)
meaning that the FE will increase exponentially and eventually
reach a plateau at steady state around S
*
½S. The rapidity with which
the curve will reach steady state directly depends on the inﬂux Vin
and be inversely proportional to the pool size [P]. A common casewhen designing ametabolic model is the presence of a dilution ﬂux
in the pool, which is a constant contribution to the molecule by
unlabelled sources (Vdil; Fig. 2C). Under these circumstances, the
mass balance equation has the form:
dPðtÞ
dt
¼ Vin þ Vdil  Vout ¼ 0 (8)
It follows that Vin ¼ Vout  Vdil. The labelling in the product pool
is therefore given by the following expression:
P*ðtÞ
½P ¼
S*
½S
Vout  Vdil
Vout

1 exp

 Vin½P t

(9)
In this case, the labelling curve will level off to the value of FE
S*
½S
VoutVdil
Vout
at steady state, decreased by the fraction VoutVdilVout <1
compared to the example in absence of dilution.
In a more complex system made of N interconnected metabolic
pools, each pool will generally receive labelling/dilution from n
incoming ﬂuxes and be drained through m ﬂuxes (Fig. 2B). The
whole system is therefore described by a set of N coupled differ-
ential equations of the following form:
dP*i ðtÞ
dt
¼
Xn
j¼1
S*j
Sj
Vjin 
Xm
k¼1
P*i
½Pi
Vkout (10)
where i ¼ 1; …;N.3.2. [1e13C] and [1,6e13C]glucose metabolism in neurons and glial
cells
The neuro-glial compartment model for energy metabolism is
an example of a complex system of metabolic pools connected by
metabolic ﬂuxes (Fig. 3A). [1e13C]glucose or [1,6e13C]glucose in-
fusions are the most common substrates used in the study of brain
energy metabolism that label glutamate and glutamine down-
stream of oxidative metabolism and neurotransmission. The
chemical shift range commonly accessible potentially allows the
detection of C4, C3 and C2 resonances of glutamate and glutamine
over time: C4 curves are usually detected separately while C3 and
C2 positions appear frequently overlapped (Glx) depending on the
sensitivity available with a given magnetic ﬁeld and on the tech-
nique of detection. The wide chemical shift range of direct 13C
detection enables typically the complete separation of the different
labelled carbon positions [22,27,29,93,100e102].
As summarised in Fig. 3B, the 13C at the positions C1 and C6 of
glucose is transferred to the C3 of pyruvate before entering the TCA
cycle. The labelling curves comprise glutamate and glutamine
located in both neurons and astrocytes: glutamate is mostly
attributed to neurons and glutamine is mainly located in astrocytes,
reported by immunohistochemical staining [103,104]. Moreover,
total glutamate concentration is usually about twice higher than
glutamine [105,106] and the neuronal TCA cycle rate is typically
higher than the glial TCA cycle rate. In other words, most of the 13C
label is transferred in neurons, which makes the 13C turnover
curves particularly sensitive to neuronal metabolism. The ﬁrst
carbon position being labelled is glutamate C4 followed by gluta-
mine C4. Since glutamate is attributed almost entirely to neurons,
the C4 labelling curve (Fig. 1D) carries the information on the
neuronal TCA cycle (VTCAn ) and the transmitochondrial ﬂux (Vx)
while the curve is rather insensitive to the neurotransmission ﬂux
(VNT) that carries additional labelling from the glial compartment
[107]. Conversely, glutamine is labelled to a greater extent from the
larger neuronal glutamate pool and the shape of its FE curve is more
sensitive to VNT, which has however a reduced impact on the ﬁrst
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commonly lower than FE of glucose (Fig. 1D), meaning that a
dilution or a net loss of labelling must occur: this is usually justiﬁed
as a consequence of glucose utilisation for non-oxidative purposes,
lactate exchange with the extracerebral compartment or incorpo-
ration of unlabelled substrates other than glucose [108].
If no other cell-speciﬁc ﬂux would be present, the C4 curves of
glutamate and glutamine would reach the same FE at steady state.
C3 and C2 curves would appear equally labelled, since there is the
same probability of labelling the two positions during the second
and further cycling of TCA cycle. However, the relative FE of the
different carbon positions is not the same in glutamine and gluta-
mate (Fig. 1D) reﬂecting distinct kinetics in the glial and neuronal
compartments. At ﬁrst, a dilution ﬂux is present in the glial
compartment due to the incorporation of glia-speciﬁc substrates
such as acetate, fatty acids and ketone bodies, decreasing the
glutamine label equally in all positions. Moreover, the anaplerotic
activity of pyruvate carboxylase has the effect of increasing the FE
at the position C2 while diluting the position C3, by simultaneously
introducing a 12C. The glutamate pool (mostly neuronal) is less
affected by the increase in the C2 FE since the neuronal mito-
chondrial metabolism has a higher impact on its labelling. There-
fore, the C3 and C2 curves of glutamate are typically close together
while FE in glutamine C2 is typically higher than the enrichment in
C3.
Detection of GABA labelling curves theoretically allows the
distinction of GABAergic neurons in the modelling strategy
(Fig. 3A), while aspartate C3 and C2 curves can be included in both
models in order to reach a more precise ﬂux estimation.
In the following paragraph we explain how ﬂux estimation is
usually performed, how the number of estimated parameters and
their precision is inﬂuenced by the noise, the number of measured
labelling curves and their temporal resolution.
3.3. Flux estimation
For the ﬂux estimation, a labelling equation is deﬁned for each
metabolic pool of the system, where the functions P
*
i ðtÞ
½Pi are deter-
mined experimentally and the parameter Vi are estimated. How-
ever, more generally, some labelling curves can be undetermined
before modelling or insufﬁciently characterized due to a poor
temporal resolution, which in turns can require some parameters to
be ﬁxed by several constraints or a priori knowledge. The
complexity of the model and the measureable metabolic parame-
ters are in tight connection with the number of accessible labelling
pools in the biochemical reaction chain under study. Globally, a
higher number of experimental labelling curves will increase the
robustness of the modelling process and the number and precision
of estimated parameters [107].
Parameter optimization in 13C metabolic modelling is often
achieved by solving the differential equations numerically by least-
square regression [26,98,109]: brieﬂy, the method will try to ﬁnd
the most appropriate set of parameters that allows minimizing the
sum of the squared differences (e.g. c2) between the labelling
curves produced by the model with the given ﬂuxes and the
experimental curves. Given an experimental turnover curve yðtiÞ
discretely determined at M time points ti and a set of parameters
V1;…;VN that generate the model simulated function
f ðV1;…;VN ; tiÞ, the cost function of the regression is given by
Ref. [26]:
c2 ¼
XM
i¼1½f ðV1;…;VN; tiÞ  yðtiÞ
2 (11)
The process will be repeated iteratively until reaching the esti-
mation of an appropriate set of parameters corresponding to theminimum of c2 that will correspond to the “best” ﬁt. However, the
analysis might fall into a local minimum [26] or a very broad
minimum, in particular when the system is underdetermined. A
ﬁrst control of the accuracy of the analysis is usually performed
with the systematic inspection of the residuals. When the residuals
of a ﬁt show a clear pattern, it might conceal a bias or incom-
pleteness in the modelling strategy, which needs revision. Addi-
tionally, the estimated results might be strongly inﬂuenced by
speciﬁc assumptions or ﬁxed parameters [42,48]. The sensitivity of
the estimated parameters upon the assumptions is often assessed
by observing their change when varying the constraints within a
reasonable range.
Another important aspect in 13C MRS is the noise level and its
impact on the parameter estimation: up to now we presented the
problem of parameter estimation, neglecting the existence of a
noise source in the experimental data and how its intensity affects
the estimation. As a matter of fact, the algorithms dedicated to least
square ﬁtting provide an estimation of the uncertainties that are
based on the assumption of a “vanishingly small” noise in the
experimental data [26] (stdevðSignalÞSignal ≪1), based on the covariance
matrix. As previously discussed, given the challenging nature of the
in vivo 13C detection, this assumption is not always valid, leaving
space for the implementation of a method that is able to assess the
impact of noise on the analysis. A common approach is to use the
Monte Carlo (MC) simulations [110,111] which are based on artiﬁ-
cial datasets with similar characteristics to the experimental data,
with different realization of noise of same power. A ﬁrst noise-free
dataset is generated from the estimated ﬂuxes, V1;…;VN obtained
from the best ﬁt of the experimental data. A set of experimental
curves (typically several hundreds) is then generated with the
addition of a speciﬁc noise realization to each noise-free turnover
curve, with the same noise characteristics as the experimental data
(SD or power). By ﬁtting the artiﬁcially generated data sets with the
same metabolic model, the method will generate a probability
distribution for each estimated parameter, reﬂecting the variability
of the ﬂux determination as a function of the experimental noise
variation. The SD or any further statistical measure on the ﬂux
probability distributions carries the information on each ﬂux pre-
cision and its reliability in the metabolic analysis. Other important
features that can be obtained from MC analyses are covariance or
correlations of the calculated ﬂuxes, pointing to their relative in-
dependence in the parameter optimization process. Strongly
correlated ﬂuxes may indicate a need for simpliﬁcation by a
reduction of the number of free parameters, typically based on a
priori knowledge from previous biochemical experiments.
Ideally, when spectra are measured dynamically, every point
should be measured with the same precision, or in other words,
every experimental point has the same “weight” in the ﬁtting
procedure. However, precision in the determination of 13C con-
centration of a given carbon position could vary along the experi-
ment, especially for low concentrationmetabolites at the beginning
of the substrate infusion. In this case the least-square ﬁtting pro-
cedure can be done through aweighted cost function, such as [112]:
c2 ¼
XM
i¼1wi
j
f ðV1;…;VN; tiÞ  yðtiÞ2
k
(12)
where the weight wi applied to each experimental point is usually
determined from the precision in the estimation of labelling con-
centration at the point ti.
13C labelling experiments typically detect a set of uptake curves
simultaneously. Therefore, the ﬁtting procedure implies the
simultaneous least-square regression for the different labelling
curves. In practice, detection of certain carbon positions over time
will be more challenging due to the relatively low FE of certain
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peaks. As a result, certain curves are determined with a lower
precision, which will generate a larger contribution to the cost
function. Dynamic data of such curves can be integrated in the
model with a corrected impact to ﬂux estimation by attributing a
weight to each of the L labelling curves measured during the
experiment [113]:
c2 ¼
XL
j¼1
XM
i¼1wij
j
fjðV1;…;VN ; tiÞ  yjðtiÞ2
k
(13)
It is to note that the cost function is weighted by the square of
the difference between the measured curves yj and the simulated
functions fj, not by their amplitude. So, a high SNR curve (such as
GluC4) will not necessarily contribute more to the cost function
than a low enrichment curve, such as GlnC2. It is the amplitude of
the dispersion of the experimental points around the model func-
tions that contributes to the cost function value.
We typically measure low FE curves (such as the C2) with higher
noise level than e.g. the C4, due to the more difﬁcult spectral
quantiﬁcation, whichwould improperly contributemore to the cost
function. Weighted regression enables then to correct for the
different SD of the measured points/curves and work with an un-
biased cost function. This method also enables equivalent ﬁtting
results of FE turnover curves or 13C concentration curves, since a
concentration scaling of the corresponding curves (and noise) is
adjusted in the cost function.
An unbiased weight attributed to each time point i of the curve j
is deﬁned by the inverse of the variance of each curve time point:
wij ¼
1
SDij
2 (14)
4. In vivo 13C brain MRS: chasing a new standard in 13C
sensitivity
Historically, advances in in vivo brain 13C MRS in animals and
humans have been highly interrelated: in the following paragraphs
the connection between the technical advances of note in the ﬁeld
of 13C MRS will be highlighted, as well as their impact on in vivo 13C
MRS in humans and in rodents, namely on spatial resolution,
metabolite detection and consequent improvements in metabolic
ﬂux modelling.
4.1. An historical perspective: 13C brain MRS in its infancy
In the early ’70s 31P MRS was frequently used in living micro-
organisms to study several phosphate-containing metabolites.
Interesting characteristics of these measurements, such as non-
invasiveness and direct access to metabolite kinetics drew atten-
tion on the possibility to use the same NMR techniques with 13C,
aimed at studying carbohydrate metabolism. The ﬁrst systematic
study on the occurrence of the 13C isotopewas actually published in
1939 [114] well before the discovery of the NMR effect and thus, the
advent of Fourier transform techniques in 1966 [115]. However,
highly enriched compounds were not available at that time.
Therefore, research focused on the radioactive 11C and 14C com-
pounds. First 13C natural abundance spectra were shown by Lau-
terbur in 1957 [116] while the ﬁrst studies on yeast, cells and
mitochondria [117e120] were made feasible with the use of FT and
newly available 13C enriched compounds [121].
Glucose metabolism was the ﬁrst to be examined with 13C MRS
experiments in yeast [118] and E. coli [122], the latter showing time
courses of by-products related to glucose catabolism. Few yearslater a ﬁrst attempt of modelling glucose uptake was made on data
collected fromyeast cells fed with [1e13C] and [6e13C] glucose with
a Michaelis-Menten kinetic model [123], while main chemical re-
actions of the TCA cycle were estimated for the ﬁrst time in cardiac
tissue in vitro [11]. Up to this point, computational methods were
still immature and magnetic ﬁelds available for research reached
approximately 2 Tesla. Moreover, techniques of 3D localization
were not yet established, hence the appearance of lipid signals
were often interpreted as free mobile lipids. In in vivo animal ex-
periments, the sensitivity issue in the small rat or rabbit brain was
often solved by putting the surface coil in direct contact with the
skull by retraction of the skin [64,68] and by opting for indirect
detection techniques [64].
In the early 90's, 13CMRSwas then applied to human volunteers:
infusion of labelled glucose in euglycemic and hyperglycemic
conditions allowed to detect dynamic data from glutamate
enrichment through TCA cycle at sufﬁcient FE [3,70,71,124]. Finally,
the introduction of automated shimming [57,58] and 3D localiza-
tion allowed a great improvement in spectral resolution: for the
ﬁrst time, 13C localized MRS identiﬁed lipid resonances as a
contribution from subcutaneous fat rather than intracranial mobile
lipids [71]. Few experiments were performed with natural abun-
dance signals [2,5,6] revealing the possibility of quantifying several
molecules involved in brain metabolism, such as glucose and myo-
Inositol, that were not accessible at the time, given the low spectral
resolution available in 1H MRS. The sudden enhancement in spec-
tral resolution opened a window for the study of brain compart-
mentation from the distinct detection of glutamate and glutamine
in the brain in vivo [4,58].
From here on, magnetic ﬁeld strengths available in clinics and
animal research ﬁeld have been experiencing a steady increase:
although the increase in B0 ﬁeld is directly connected with sensi-
tivity by reducing peak overlap, researchers had to cope with
higher power demand for broadband decoupling and spatial
localization, which is essential in in vivo applications. Limitations in
power depositions are particularly strict for human subjects and
required speciﬁc attention in developing new strategies in coil
development and sequence design as discussed above.4.2. Rodent models for 13C MRS in vivo
Rodents are widely employed in preclinical research on brain
diseases, thanks to their proximity to the human genome and even
more similarities to the human immune system, which supports
the development of similar pathologies and reproduces treatment
response [125]. Other characteristics, such as the possibility to
develop genetically engineered species among mice and rats
opened the way to reproducing disease models that preserve the
same genetic aberration of the human counterpart [125].
In this context, MR techniques offer a non-invasive approach to
investigate metabolism in healthy animal models and in models of
brain diseases in vivo, preserving brain cells in their natural
microenvironment, namely brain parenchyma and BBB, which is
speciﬁcally known to inﬂuence drug response. In vivo 13C MRS re-
quires the injection of expensive labelled substrates, which makes
the use of small animal species of advantage in terms of amount of
tracer needed per subject. Besides this, rodent animal models
provide easier handling procedures and are less expensive to pur-
chase and maintain than other typical research animals, such as
primates. Although mice are the most widely used animal model in
biomedical research, MRS studies of low-gyromagnetic ratio nuclei
have to date focused mainly on the rat brain due to its larger size
(~1200 mg vs ~400 mg [126]), facilitated surgical interventions and
maintenance of normal physiology.
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First feasibility studies of in vivo brain 13C MRS were carried out
on rats [64,65] with indirect detection techniques shortly followed
by several human studies: after the ﬁrst attempt of measuring
glucose uptake and metabolism in human subjects [4,71], several
in vivo measurements in rats were performed at 7 Tesla [18,19,127]
to obtain a more detailed measurement of brain metabolism using
direct 13C detection, providing more distinguishable metabolite
resonances. All these measurements were performed with surface
coil detection only. Lipid resonances were eliminated by subtrac-
tion of a spectral baseline acquired prior to substrate infusion.
Spectral quality suffered from a relatively large linewidth
(40e60 Hz on water signal [18,127]). Introduction of improved
localized shimming procedures on ﬁrst and second order coils
[58,128] and localization strategies based on ISIS scheme in human
studies [129,130] improved dramatically the spectral resolution on
the metabolites (linewidth <10 Hz) allowing the measurement of
extended time courses of glutamate and glutamine at the position
C4 [131] even at low ﬁeld strength [129]. Finally, distinct mea-
surements of C4, C3 and C2 amino acid resonances upon infusion of
[1e13C]glucose in humans opened the way to model brain meta-
bolism with a two-compartment approach, which accounts for
neuro-glial trafﬁcking [100,127]. Similar experiments were per-
formed in rats at 9.4 Tesla in typical volumes of 510 mL [102]:
turnover curves of glutamate and glutamine C4 and C3 together
with aspartate C3 were included in the model, while data on C2
turnover curves of glutamate and glutamine were not reported.
Metabolic ﬂux analysis of neurons and astrocytes was similarly
investigated in rats with [2e13C] and [5e13C]glucose at 7 Tesla [19]
although in unlocalized spectra with lipid baseline subtraction.
Regional glucose metabolism in rats was later assessed at higher
spatial resolution (up to 25 mL) achievedwith indirect detection at 7
Tesla in the rat brain [20]: a two compartmental approach in the
modelling strategy was kept to model the distinct C4 resonances
and the sum of C3 peaks for glutamate and glutamine, including a
priori knowledge imposed on glial TCA cycle and anaplerotic ﬂux.
GABAergic metabolism was ﬁnally implemented in a three-
compartment model (Fig. 3A) for the ﬁrst time by integrating
ex vivo and in vivo data measurements with direct detection in a
360 mL voxel [101]. Similar experiments under infusion of [2e13C]
acetate could distinguish between C3 peaks of glutamate and
glutamine in a 196 mL volume at 7 Tesla [132]. Again, labelling
curves determined in vivowere supplemented with ex vivo data on
C3 peaks to allow the use of a two-compartment model.
Detection of in vivo time courses of GABA peaks remained
challenging at 7 Tesla due to the relatively low concentration of this
metabolite and spectral overlap. By raising the ﬁeld strength to 9.4
and 14.1 Tesla, an increasing number of by-products were
measured in vivo: for the ﬁrst time distinct detection of C4 and C3
time courses of glutamine and glutamate were reported with in-
direct detection technique during infusion of [2e13C]acetate [21,51]
in relatively small voxels (144e180 mL). Moreover, since acetate is a
substrate selectively taken up by astrocytes, it enters the glial TCA
cycle at the level of acetyl-CoA and labels the neuronal glutamate
through the glial glutamine pool (Fig. 3A). The speciﬁc label ﬂowing
from the astrocytic compartment increases the sensitivity by
measuring the glial TCA cycle and neurotransmission with a two-
compartmental model [99].
Direct 13C detection in the rat brain remained conﬁned to larger
voxels compared to the standard reached with indirect detection
(~300 mL for resolved C4, C3 and C2 of Glu/Gln): recent studies
could take advantage of larger spectral dispersion at ultrahigh
ﬁelds ﬁnally measuring complete in vivo time courses of C4, C3 and
C2 positions of glutamate and glutamine, as well as a large cohort ofby-products linked to glucose metabolism [22,23] as previously
demonstrated [50]. Dynamic data collected over 5 h of [1,6e13C]
glucose were treated either with a neuroglial modelling approach
or a three-compartment model (Fig. 3A) to discern GABAergic and
glutamatergic neuronal activity.
To date, 13C MRS in rats has reached relatively good standard in
spatial resolution in ultrahigh ﬁeld: experiments mainly reﬂect
metabolism of the cortex and hippocampus which are closer to the
brain surface and therefore easier to detect with surface coil con-
ﬁgurations. Studies in healthy rats contributed noticeably to the
understanding of brain function in terms of substrate consumption
and metabolic rate assessment for speciﬁc cell populations, as
compared to the ﬁrst measurements of global TCA cycle rates in the
rat brain [65,133]. Direct and indirect detection techniques
contributed to gain a quantitative understanding of GABAergic and
glutamatergic neurotransmission under physiological conditions.
4.4. 13C MRS in the mouse brain in vivo
Although in vivo 13C MRS in rats contributed to elucidate basic
mechanisms of brain metabolism with an appreciation of cell-
speciﬁc roles in neuroenergetics, the further application of this
technique to mice is of great interest. In fact, a wider variety of
genetically engineered species are available among mice. These
models are employed in biomedical research to replicate genetic
aberrations that are linked to pathogenesis and mechanisms of
many human diseases. Mice are the most used animal models in
this ﬁeld and a more extensive literature on in vitro and in vivo
studies is available.
Given the limitations in 13C detection in vivo in small volumes,
13C MRS in mice was at ﬁrst applied to tissue brain extracts with
indirect detection [95]: these results gave a quantitative apprecia-
tion of neuroglial metabolism with their respective regional dif-
ferences and distinction of GABAergic and glutamatergic
neurotransmission. A ﬁrst proof of concept of the feasibility of
in vivo detection was made at 7 Tesla with a direct detection
sequence applying 1H polarization transfer to 13C, combined to 1H
broadband localization [50] in a volume of interest of 175 mL [27].
Complete time courses of glutamate and glutamine at the positions
C4 and C3 were reported upon infusion of [1,6e13C]glucose. These
results were later compared by Sack et al. with in vivo acquisition
performed with a surface coil cooled at cryogenic temperatures
[41] on mice infused with [1e13C] Glc: this technology allowed
distinct detection of C4, C3 and C2 resonances of glutamate and
glutamine together C4 and C2 peaks of GABA. Position C3 of GABA
was hidden below noise level in dynamic acquisitions with a
temporal resolution of 12 min. The authors reported that theoret-
ically, an improvement in the SNR of 6.5 could be reached with the
cryo-technique if acquiring spectra in the same experimental
conditions as in Ref. [27] (with polarization transfer and infusion of
[1,6e13C] Glc).
More recently, 13C MRS has been applied with increased spectral
dispersion and SNR at 14.1 Tesla in a voxel of 112 mL in the central
brain [29] by infusing [1,6e13C]glucose: this ﬁnally allowed the
detection of complete time courses of C4, C3 and C2 peaks of
glutamate and glutamine and a wide range of glucose by-products
during 5 h of infusion. Complete time courses of glutamate and
glutamine were integrated in a two-compartment model for
neuroglial metabolism reaching a quantitative understanding of
the respective compartments by determining TCA cycle rate in
neurons (VTCAn ) and astrocytes (Vg), pyruvate carboxylase activity
(VPC), transmitochondrial ﬂux (Vx) and neurotransmission (VNT).
Higher spatial resolutionwas achievedwith 1H-[13C]MRS at 14.1
Tesla in a voxel of only 60 mL placed in the frontal brain (cortex and
striatum): measurements included the C4 position of glutamate
Fig. 4. In vivo 13C direct detection in the rat (AeC) andmouse brain (BeD) at 9.4 and 14.1 Tesla respectively, during infusion of [1,6e13C2]glucose. Direct detectionwas achievedwith semi-
adiabaticDEPTpolarization transfer sequence [50]. Rat spectrawere acquired ina320mL voxel (5 88mm3) including thecortex andpartof thecentral brainandmousespectra in112mL
(3.6 6.9 4.5 mm3) placed in a central region. Both animals were infused with a 5 min exponentially-decaying bolus of 99%-enriched [1,6e13C2]glucose followed by 5 h of continuous
infusion with 70%-enriched [1,6e13C]glucose. Dynamic acquisitions (AeB) at temporal resolution of 10.2 min starting after the bolus (lb ¼ 20 Hz between 5 and 150 min; lb ¼ 10 Hz at
160min). Steadystate spectra (CeD)are acquired in the same regions for61.2minafter4hof [1,6e13C2]glucose infusion (lb¼20Hz).Mousespectra showadistinctmetabolicproﬁle linked
to thepredominanceof thestriatuminthevolumeof interest, suchaspronouncedGABAand lactatepeaks,due to their relatively large concentration in this region [105]. To followthe fateof
13C-glucose through the different by-products, please refer to Fig. 3B. 13C-[1H] quadrature coils used for the spectra acquisition in rats and mice are shown respectively in E and F. Ab-
breviations: volume of interest (VOI), glucose (Glc), glutamate (Glu), glutamine (Gln), N-acetylaspartate (NAA), aspartate (Asp), g-aminobutyric acid (GABA), lactate (Lac), alanine (Ala).
M. Lai et al. / Analytical Biochemistry 529 (2017) 229e244 241and glutamine and distinct C4, C3 and C2 time courses of GABA, as
well as C3 resonance of lactate and alanine as well as aspartate C2
[28]. C3 and C2 positions of glutamate and glutamine appeared
overlapped, which limited the choice of the modelling strategy to a
single compartment to avoid ﬁxing a priori ﬂux values in a two-
compartment modelling approach. An MRS-derived input func-
tion could be included in the model with the accessibility of the 13C
lactate FE during the experiment, whereas in previous studies with
direct detection the input function had to be imposed as a priori
knowledge derived from standardized infusion protocols [29].
Indeed, most NMR sequences for indirect detection are able to
quantify the concentration of 13C and 12C simultaneously allowing a
direct measurement of the FE without the requirement of as-
sumptions on the pool size over the experiment, as previously
demonstrated [51]. Successful results in the detection of glutamate,
glutamine and GABA resonances were similarly obtained in a vol-
ume of 16.5 mL in the dorsal hippocampus [31] and of barely 8.7 mL
in the hypothalamic region [30]: time courses of glutamate and
glutamine C4 were detected separately as well as GABA at the po-
sitions C2, C3 and C4. This constitutes a noticeable challenge since
coil detection power diminishes with distance from the volume of
interest, which greatly increases in the hypothalamus, located at
the bottom of the brain. Metabolic modelling of the aforemen-
tioned results using a one-compartment model for brain meta-
bolism assessed averaged TCA cycle (VTCA), transmitochondrial ﬂux
(Vx), neurotransmission rate (VNT) and pyruvate dilution ﬂux (Kdil)
[28,30]. Although these results constituted a novelty in the ﬁeld of
13C in vivo detection in the mouse brain, given the exceptionally
small size of the volume of interest, two-compartmental modelling
of glucose metabolism remains a prerogative of experiments per-
formed with direct detection techniques in which glutamate and
glutamine resonances appear fully separated [27,29], leading to
additional estimation of TCA cycle rate in neurons (VTCAn ) and as-
trocytes (Vg) and pyruvate carboxylase activity (VPC). On the whole,
these outcomes suggest an increased detection power in 13C
detection in vivo that leads toward quantiﬁcation of region-speciﬁc
metabolic ﬂuxes in the mouse brain.
5. Conclusion
In the recent years, in vivo brain 13C MRS has reached a level of
relative maturity in animal experimentation, although the tech-
nique remains intrinsically challenging and requires high level in-
strumentations and complex knowledge. In conclusion, present
standards make the detection of highly detailed metabolic infor-
mation in the mouse brain possible without drawing upon cryo-
genic cooling of the coils or hyperpolarized substrates. Spectral
quality reaches nowadays similar standards as in rat experiments,
despite the reduced voxel size, thanks to the utilization of ultrahigh
ﬁelds (Fig. 4). Speciﬁc insights on regionalmetabolism in themouse
brain and speciﬁc roles of GABAergic and glutamatergic neuronal
metabolism need to be further investigated remaining so far
conﬁned to ex vivo investigations. The use of in vivo brain 13C MRS
in mice speciﬁc models of brain diseases is another promising
application.
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